Back to search
CD30 Positive Primary Mediastinal Large B-cell Lymphoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which CD30 Positive Primary Mediastinal Large B-cell Lymphoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which CD30 Positive Primary Mediastinal Large B-cell Lymphoma trials you may qualify forThis is a phase 1 study to evaluate safety and dose-limiting toxicity of autologous CD30.CAR-T in subjects with relapsed or refractory CD30+ Non-Hodgkin Lymphom…
This is a Phase I/II multicenter single arm non-randomized open label study of the investigational drug, brentuximab vedotin, given in combination with routine…
Study Objectives Primary: • To determine the antitumor efficacy of single-agent Brentuximab vedotin (1.8 mg/kg administered intravenously every 3 weeks) as mea…
This phase II trial studies how well brentuximab vedotin, bendamustine, and rituximab work in treating patients with B-cell non-Hodgkin lymphoma that has return…